Physician profile
Michael Stirling
NPI 1306338413
$22,875.41
in general payments reported to CMS, 2019-2025
52 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,446 · 2022: $11K · 2023: $1,721 · 2024: $5,894 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173 · Travel and Lodging: $2,396 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,145 · Consulting Fee: $729 · Education: $79.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.45 |
| Travel and Lodging | $2,396.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,145.00 |
| Consulting Fee | $728.75 |
| Education | $79.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $7,086.11 | 2022 | |
| Novo Nordisk INC | $5,300.45 | 2021-2025 | Rivfloza |
| Boston Scientific Corporation | $931.02 | 2024-2025 | Ams 700 Cxr Rte Kit, Ams 700 |
| Dexcom, INC. | $829.93 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $729.46 | 2021-2023 | Tavneos |
| Abbott Laboratories | $701.49 | 2021-2023 | Freestyle Libre 3, Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $647.21 | 2021-2023 | Cycloset |
| Myriad Genetic Laboratories, INC. | $587.54 | 2023-2025 | Myrisk, Prolaris |
| Lilly USA, LLC | $471.65 | 2021-2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $465.66 | 2021-2022 | |
| Antares Pharma, INC. | $422.23 | 2023-2025 | Xyosted, Tlando |
| Janssen Biotech, INC. | $359.62 | 2021-2024 | Erleada, Akeega |
| Tolmar, INC. | $326.69 | 2024-2025 | Jatenzo, Eligard |
| Astrazeneca Pharmaceuticals LP | $310.48 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.07 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stirling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.